ABUS Forecast and Technical Stock Analysis
Buy candidate since 2019-12-13 PDF
Arbutus Biopharma Corporation fell by -2.51% in the last day ( Friday, 13th Dec 2019 ) from $2.39 to $2.33 and has now fallen 3 days in a row. During the day the stock fluctuated 3.43% from a day low at $2.33 to a day high of $2.41. The price has been going up and down for this period, and there has been a 39.52% gain for the last 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -131 177 shares and in total 197 526 shares bought and sold for approximately $460 236.00.
- 30 day high of the ABUS stock price was $2.49 and low was $1.44.
- 90 day high was $2.49 and low was $0.82.
- 52 week high for Arbutus Biopharma Corporation - $4.78 and low - $0.82.
Arbutus Biopharma Corporation lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $2.43 will firstly indicate a stronger raising rate. Given the current short-term trend, the stock is expected to rise 49.76% during the next 3 months and, with 90% probability hold a price between $1.97 and $3.63 at the end of this period.
Arbutus Biopharma Corporation holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $2.33. On a fall, the stock will find some support from the long-term average at approximately $1.64. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Wednesday December 11, 2019, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
RSImin/max Values: [ 25 - 75 ]
The stock holds a RSI14 at 84 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
* Stockinvest.us uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behaviour.
Support & Resistance
Arbutus Biopharma Corporation finds support from accumulated volume at $2.26.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.08 between high and low, or 3.43%. For the last week the stock has had a daily average volatility of 5.50%.
The stock is overbought on RSI14 and lies in the upper part of the trend. Normally this may pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.
Our recommended stop-loss: $2.17 (-6.76%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 84 and this increases the risk substantially. There is a sell signal from pivot top found 2 day(s) ago.)
5.50 %Average volatility
Very Low Low Medium High Very High
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since last evaluation from a Hold/Accumulate to a Buy Candidate candidate.
|ABUS $2.33 ($-0.06 -2.51%)|
ABUS is down $0.06 today, but where's it headed in 2020?
|Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month system that more than doubles the S&P 500.
This report is free today for StockInvest.us readers.
Click here – the ABUS analysis is free »
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 8.000 stocks usually only a few will trigger a Golden Star Signal per day!